Program Information
Session Highlights for March 6 and 7
March 6, 2006
09:00-12:30 - Graduates Session
With Speakers from the DIA and National Health Authorities to discuss:
- Global DIA Activities
- Drug Development and Registration Process
- Job Opportunities in Industry & Health Authorities
- 13:30-14:30DIA Welcome and Awards CeremonyDIA Distinguished Career and
Outstanding Services Awards Ceremony
- 14:30-15:30 - Plenary Session Part 1
EU INNOVATION AND COMPETITIVENESSIntroduction by the Programme Co-Chairpersons
Iman Barilero, Johnson & Johnson PRD, UK
Marie Dray, International Regulatory Affairs Group, USA
Key Note Speakers:Georgette Lalis,European Commission,
DG Enterprise and Industry, Belgium Jean-Franois Dehecq,sanofi-aventis, France
- 16:00-17:30
Plenary Session Part 2
EU INNOVATION AND COMPETITIVENESS:
PRACTICAL IMPLICATIONS FOR AND
INVOLVEMENT OF THE STAKEHOLDERSModerators:
Iman Barilero, Johnson & Johnson PRD, UK and
Philip Brown, SCRIP, UKPanelists:
Thomas Lonngren, EMEA, EU
Martin Terberger, European Commission, Belgium
Jean Marimbert, AFSSAPS, France
Yann Le Cam, EURORDIS, France
18:00-21:00
Buffet Reception
March 7, 2006
- Late breaking news:
Addition to EuroMeeting Programme,
Tuesday, March 7
13:00-13:45
Special Session:
An Assessment of the Community System of Pharmacovigilance
Session Moderator: Marie A. Dray
Speaker: Peter Arlett, MD, European Commission, Europe
The European Commission-sponsored study An Assessment of the Community System of Pharmacovigilance was made public in February 2006 and the Commission has launched a public consultation on its results including an invitation to comment on the strengths and weaknesses of the Community System. As part of this consultation, Dr. Arlett will present the study report and attendees will be invited to make comments and pose questions on the Community System of Pharmacovigilance.
- 09:00-18:30
Poster Session/Student Poster Session
Posters selected by the review committee, addressing similar topics to those in the programme, will be on display in the exhibition area. Presenters will make themselves available to discuss their work during the coffee and lunch breaks on Tuesday at Le Palais des Congres.The poster review committee will select the three best student posters, and the winning authors will receive a EuroMeeting Student Poster Prize. The Prizes will be awarded at the student poster award ceremony on Tuesday, March 7, at 17:30 by the DIA booth in the exhibition area.
- 18:30-20:00
French Agency Satellite Meeting
THE INVOLVEMENT OF FRANCE IN THE EUROPEAN NETWORKS FOR EVALUATION AND MONITORING OF HEALTH PRODUCTSGeneral Presentation of AFSSAPS:Missions and Goals - Risk Assessment and Management
Jean Marimbert, AFSSAPS, FranceRound Table Discussion on the Common Vision on Clinical Trials in France with Representatives of LEEM, INSERM and AFSSAPS**If you are registered for the EuroMeeting, then you will have access to enter in the satellite meeting without registering separately.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
